TScan Therapeutics, Inc. (TCRX)
Fuera de horario:
TScan Therapeutics, Inc.
830 Winter Street
Waltham, MA 02451
United States
857 399 9500
https://www.tscan.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 154
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Gavin MacBeath Ph.D. | CEO & Director | 853.51k | N/D | 1970 |
| Dr. Zoran Zdraveski J.D., Ph.D. | Chief Legal & Strategy Officer and Company Secretary | 657.2k | N/D | 1970 |
| Dr. Stephen J. Elledge Ph.D. | Co-Founder & Chairman of Scientific Advisory Board | N/D | N/D | N/D |
| Mr. Tomasz Kula Ph.D. | Co-Founder & Member of Advisory Board | N/D | N/D | N/D |
| Mr. Jason A. Amello | CFO & Treasurer | N/D | N/D | 1968 |
| Dr. Justin McCue Ph.D. | Chief Technology Officer | N/D | N/D | N/D |
| Ms. Ann Hargraves | Senior Vice President of Human Resources | N/D | N/D | N/D |
| Dr. Shrikanta Chattopadhyay M.D. | Senior VP & Head of Translational Medicine | N/D | N/D | N/D |
| Mr. Ray Lockard M.B.A. | Senior Vice President & Head of Quality | N/D | N/D | N/D |
| Mr. Jim Murray | Senior VP & Head of Development Operations | N/D | N/D | N/D |
Descripción
TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Gestión corporativa
La calificación ISS Governance QuickScore de TScan Therapeutics, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
